Skip to content

DERM — Hedge Fund Holders & Catalysts | BiotechEdge

BiotechEdge New: AI Signals

Catalysts Convergence Squeeze Signals Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›Journey Medical Corp (DERM)

Journey Medical Corp

DERM

Held by 1 specialist biotech fund

1 fund opened new positions.

Share

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

1.5/10

1 fund opened new positions

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

●●

No recent insider activity●●

No upcoming catalysts●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Tang Capital ManagementNew

AI Signal

Signal Note: Tang Capital Initiates $14.3M Position in Journey Medical (DERM)

Tang Capital's entry into DERM—a dermatology-focused pure-play—signals conviction in a near-term catalyst, likely tied to FDA decisions or commercial inflection on Journey's lead assets (acne and rosacea franchises). The $14.3M position size (1.85M shares) represents meaningful conviction from an event-driven specialist with a track record in biotech timing.

Unlock full AI analysis — 14-day free trial

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ATang Capital Management8.0%May 15, 2025

SC 13GTang Capital Management7.3%Nov 29, 2024

Position Details

Tang Capital ManagementNEWFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

AVIR1 fund ZYME1 fund META1 fund MIRM1 fund MRNA1 fund NMRA1 fund NKTX1 fund NUVL1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: